Get the Stockscreener App
0.59
50.42%
-0.60
After Hours:
.59
Orgenesis Inc stock is traded at $0.59, with a volume of 102.
It is down -50.42% in the last 24 hours and down -50.42% over the past month.
See More
Previous Close:
$1.19
Open:
$0.59
24h Volume:
102
Relative Volume:
1.36
Market Cap:
$N/A
Revenue:
$1.04M
Net Income/Loss:
$-49.01M
P/E Ratio:
-0.0531
EPS:
-11.109
Net Cash Flow:
$-17.34M
1W Performance:
-50.42%
1M Performance:
-50.42%
6M Performance:
-50.42%
1Y Performance:
-86.10%
1-Day Range:
$0.59
$0.59
1-Week Range:
$0.59
$0.59
52-Week Range:
$0.59
$1.19
Orgenesis Inc Stock (ORGS) Company Profile
Compare ORGS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGS
Orgenesis Inc
|
0.59 | 0 | 1.04M | -49.01M | -17.34M | -11.11 |
VRTX
Vertex Pharmaceuticals Inc
|
447.97 | 110.97B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
621.52 | 65.81B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
838.49 | 51.03B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.06 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.63 | 32.53B | 742.00K | -1.37B | -1.07B | -7.0731 |
Orgenesis Inc Stock (ORGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-18 | Initiated | Dawson James | Buy |
Orgenesis Inc Stock (ORGS) Latest News
Orgenesis Inc stock (US68621F1021): delisting to OTC puts spotlight on business model and risks - AD HOC NEWS
Orgenesis stock (US68621F1021): cell and gene therapy specialist updates investors amid ongoing rest - AD HOC NEWS
Orgenesis Inc. (ORGS) Surges 79,400% on Penny Stock Rebound - Meyka
Corvus Pharmaceuticals Reports Positive Final Phase 1 Results for Soquelitinib in Atopic Dermatitis at SID 2026 Annual Meeting 16 - Minichart
Orgenesis stock (US68621F1021): Recent clinical trial progress draws investor attention - AD HOC NEWS
MSN Money - MSN
Orgenesis | DEF 14A: Definitive information statements - Moomoo
Competitive Analysis: Key Market Leaders and Emerging - openPR.com
Top Companies Developing Cell Therapy Treatments For Diabetes in 2026 - BioInformant
ACNB Corporation Files Q1 2026 Results and Press Release with SEC – Financial Statements and Key Disclosures - Minichart
ORGS | ORGENESIS INC Insider Trading - Quiver Quantitative
Viral Vector Production (Research-use) Market Size to Surpass USD 8.51 Billion by 2035 - BioSpace
Gold, Silver Futures Rise Pre-Bell as Sliding Crude Oil Futures Help Limit Inflation Concerns - marketscreener.com
Orgenesis Inc stock (US68621F1021): Is its cell therapy pivot strong enough to unlock biotech upside - AD HOC NEWS
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
ORGS (Orgenesis) PB Ratio : (As of Mar. 31, 2026) - gurufocus.com
Stock List: Research Stocks from Around the World - GuruFocus
Europe Stocks: Research Stocks from Europe Stock Market - GuruFocus
Orgenesis Inc. 2024 Annual 10-K Report: Financials, Equity, and Major Agreements Overview - Minichart
ORGS: Severe liquidity issues and a $49M net loss raise substantial doubt about ongoing operations - TradingView
Orgen 2023 Form 10-K: $1.035M Revenue, $(49.01)M Net Loss - TradingView
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio - StreetInsider
Okogen Expands Antiviral Pipeline with Ranpirnase Acquisition, Targeting Multiple Therapeutic Areas - citybuzz.co
Okogen, Inc. acquired Global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc.. - marketscreener.com
Orgenesis Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Orgenesis Inc stock advances on cellular therapy breakthroughs amid biotech funding surge - ad-hoc-news.de
Orgenesis Inc stock advances on new cell therapy partnership amid biotech rally - AD HOC NEWS
Orgenesis Expands Board and Appoints New Chief Financial Officer - The Globe and Mail
Orgenesis appoints new directors and chief financial officer - Investing.com South Africa
Orgenesis appoints new directors and chief financial officer By Investing.com - Investing.com Australia
Orgenesis adds Adam Pelavin and Yaron Adler to board; Doug Karriker named CFO - TradingView
Orgenesis Inc. Appoints Doug Karriker as Chief Financial Officer, Effective March 10, 2026 - marketscreener.com
Patience Required for Orgenesis Investors as Strategic Model Takes Shape - AD HOC NEWS
The Truth About Orgenesis Inc (ORGS): Tiny Biotech, Huge Hype – But Is It Worth Your Money? - AD HOC NEWS
Orgenesis (NASDAQ:ORGS) Trading Up 300% – Here’s What Happened - Defense World
GLP-1 Receptor Agonist Market to Witness Massive Growth by 2033 | Perrigo Company PLC, 3M Company, Bausch Health - Weekly Voice
Nasdaq proposes 'fast entry' rule to speed up index inclusion of large new listings - marketscreener.com
Orgenesis Issues Alpha Warrant in New Financing Deal - TipRanks
Orgenesis issues warrant for 3.29 million shares tied to $1 million loan - Investing.com
Orgenesis Signs Warrant Issuance Agreement With Alpha Prosperity Fund - TradingView
The Truth About Orgenesis (ORGS): Tiny Biotech, Massive Hype – But Should You Touch It? - AD HOC NEWS
Is Orgenesis Inc. (45O) stock a safe buy pre earnings2025 Earnings Surprises & Stock Timing and Entry Methods - Улправда
Retail Trends: Is Orgenesis Inc 45O stock a safe buy pre earnings2025 Market WrapUp & AI Powered Buy/Sell Recommendations - moha.gov.vn
Aug Gainers: Is Orgenesis Inc 45O stock a safe buy pre earningsInflation Watch & Verified Swing Trading Watchlists - moha.gov.vn
Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule - marketscreener.com
Published on: 2025-12-23 22:10:30 - earlytimes.in
Regenerative Therapies Market Forecast Through 2032 - openPR.com
Statera Biopharma (NASDAQ:STAB) vs. Orgenesis (NASDAQ:ORGS) Financial Contrast - Defense World
Orgenesis Inc Stock (ORGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
3.14%
Cap:
|
Volume (24h):